Skip to main content

Table 1 Characteristics of patients

From: The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors

Characteristic

Cohort 1 N (%)

Cohort 2 N (%)

Cohort 3 N (%)

No. of patients, N

60

14

9

Sex

 Male

42 (70 %)

8 (57.1 %)

6 (66.7 %)

 Female

18 (30 %)

6 (42.9 %)

3 (33.3 %)

Age, median years (range)

54 (27–81)

59.5(40–76)

65 (42–82)

Tumor classification

 Cholangiocarcinoma

10 (16.7 %)

0

2 (22.2 %)

 Colon cancer

7 (11.7 %)

1 (7.1 %)

0

 Gastric cancer

7 (11.7 %)

0

0

 Lung cancer

11 (18.3 %)

4 (28.6 %)

2 (22.2 %)

 Primary liver cancer

25 (41.7 %)

1 (7.1 %)

2 (22.2 %)

 Other

0

8 (57.1 %)

3 (33.3 %)

TNM staging

 Stage I

3 (5 %)

1 (7.1 %)

2 (22.2 %)

 Stage II

4 (6.7 %)

0

1 (11.1 %)

 Stage IIIA

12 (20 %)

2 (14.3 %)

1 (11.1 %)

 Stage IIIB

2 (3.3 %)

0

0

 Stage IIIC

9 (15 %)

4 (28.6 %)

1 (11.1 %)

 Stage IV

27 (45 %)

6 (42.9 %)

3 (33.3 %)

 Missing data

3 (5 %)

1 (7.1 %)

1 (11.1 %)

Adjuvant therapeutic strategies

 Without

24 (40 %)

5 (35.7 %)

7 (77.8 %)

 With

36 (60 %)

9 (64.3 %)

2 (22.2 %)

 Chemotherapy

18 (30 %)

6 (42.9 %)

1 (11.1 %)

 Radiation therapy

8 (13.3 %)

1 (7.1 %)

1 (11.1 %)

 Physiotherapy

2 (3.3 %)

0

1 (11.1 %)

 Interventional treatment

9 (15 %)

2 (14.3 %)

0

 Molecular targeted therapy

2 (3.3 %)

1 (7.1 %)

0